Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Benign Prostatic Hyperplasia (BPH) Drugs Market 2018, Forecast to 2023
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
Scope of the Report:
This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
The worldwide market for Benign Prostatic Hyperplasia (BPH) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with sales, revenue, and price of Benign Prostatic Hyperplasia (BPH) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Benign Prostatic Hyperplasia (BPH) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Scope of the Report:
This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
The worldwide market for Benign Prostatic Hyperplasia (BPH) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Astellas Pharma
- Eli Lilly
- GlaxoSmithKline
- Sanofi
- ADC Therapeutics
- Bayer HealthCare
- Bristol-Myers Squibb
- Valeant Pharmaceuticals
- Endo Pharmaceuticals
- Foresee Pharmaceuticals
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
- Alpha-Blocker
- Phosphodiesterase Type-5 Inhibitors
- 5-Alpha-Reductase Inhibitors
- Men
- Women
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with sales, revenue, and price of Benign Prostatic Hyperplasia (BPH) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Benign Prostatic Hyperplasia (BPH) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
1 MARKET OVERVIEW
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Alpha-Blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 5-Alpha-Reductase Inhibitors
1.3 Market Analysis by Applications
1.3.1 Men
1.3.2 Women
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 MANUFACTURERS PROFILES
2.1 Astellas Pharma
2.1.1 Business Overview
2.1.1.1 Astellas Pharma Description
2.1.1.2 Astellas Pharma Headquarter, Main Business and Finance Overview
2.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.1.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.1.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.2 Eli Lilly
2.2.1 Business Overview
2.2.1.1 Eli Lilly Description
2.2.1.2 Eli Lilly Headquarter, Main Business and Finance Overview
2.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.2.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.1.1 GlaxoSmithKline Description
2.3.1.2 GlaxoSmithKline Headquarter, Main Business and Finance Overview
2.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.3.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.3.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.4 Sanofi
2.4.1 Business Overview
2.4.1.1 Sanofi Description
2.4.1.2 Sanofi Headquarter, Main Business and Finance Overview
2.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.4.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.4.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.5 ADC Therapeutics
2.5.1 Business Overview
2.5.1.1 ADC Therapeutics Description
2.5.1.2 ADC Therapeutics Headquarter, Main Business and Finance Overview
2.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.5.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.5.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.1 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.2 Global ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.6 Bayer HealthCare
2.6.1 Business Overview
2.6.1.1 Bayer HealthCare Description
2.6.1.2 Bayer HealthCare Headquarter, Main Business and Finance Overview
2.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.6.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.6.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.1 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.2 Global Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.7 Bristol-Myers Squibb
2.7.1 Business Overview
2.7.1.1 Bristol-Myers Squibb Description
2.7.1.2 Bristol-Myers Squibb Headquarter, Main Business and Finance Overview
2.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.7.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.7.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.1 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.2 Global Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.8 Valeant Pharmaceuticals
2.8.1 Business Overview
2.8.1.1 Valeant Pharmaceuticals Description
2.8.1.2 Valeant Pharmaceuticals Headquarter, Main Business and Finance Overview
2.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.8.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.8.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.1 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.2 Global Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.9 Endo Pharmaceuticals
2.9.1 Business Overview
2.9.1.1 Endo Pharmaceuticals Description
2.9.1.2 Endo Pharmaceuticals Headquarter, Main Business and Finance Overview
2.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.9.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.9.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.1 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.2 Global Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.10 Foresee Pharmaceuticals
2.10.1 Business Overview
2.10.1.1 Foresee Pharmaceuticals Description
2.10.1.2 Foresee Pharmaceuticals Headquarter, Main Business and Finance Overview
2.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.10.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.10.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.1 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.2 Global Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION, BY MANUFACTURER
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.4.2 Top 5 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET ANALYSIS BY REGIONS
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2013-2018)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2013-2018)
4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
5 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
5.1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.1.4 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.1.5 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
5.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
5.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
5.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
5.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
6 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
6.1.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.4 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.5 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.6 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.7 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
6.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
6.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
7 ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
7.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.5 Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.6 India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
8 SOUTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
8.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
8.1.3 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.1.4 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.1.5 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
8.2.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
8.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
8.3.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
8.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
8.4.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
9 MIDDLE EAST AND AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.4 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.5 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.7 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
10 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SEGMENT BY TYPE
10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2013-2018)
10.2 Alpha-Blocker Sales Growth and Price
10.2.1 Global Alpha-Blocker Sales Growth (2013-2018)
10.2.2 Global Alpha-Blocker Price (2013-2018)
10.3 Phosphodiesterase Type-5 Inhibitors Sales Growth and Price
10.3.1 Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2013-2018)
10.3.2 Global Phosphodiesterase Type-5 Inhibitors Price (2013-2018)
10.4 5-Alpha-Reductase Inhibitors Sales Growth and Price
10.4.1 Global 5-Alpha-Reductase Inhibitors Sales Growth (2013-2018)
10.4.2 Global 5-Alpha-Reductase Inhibitors Price (2013-2018)
11 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SEGMENT BY APPLICATION
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2013-2018)
11.2 Men Sales Growth (2013-2018)
11.3 Women Sales Growth (2013-2018)
12 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET FORECAST (2018-2023)
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2018-2023)
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2018-2023)
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Data Source
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Alpha-Blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 5-Alpha-Reductase Inhibitors
1.3 Market Analysis by Applications
1.3.1 Men
1.3.2 Women
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 MANUFACTURERS PROFILES
2.1 Astellas Pharma
2.1.1 Business Overview
2.1.1.1 Astellas Pharma Description
2.1.1.2 Astellas Pharma Headquarter, Main Business and Finance Overview
2.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.1.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.1.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.2 Eli Lilly
2.2.1 Business Overview
2.2.1.1 Eli Lilly Description
2.2.1.2 Eli Lilly Headquarter, Main Business and Finance Overview
2.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.2.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.1.1 GlaxoSmithKline Description
2.3.1.2 GlaxoSmithKline Headquarter, Main Business and Finance Overview
2.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.3.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.3.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.4 Sanofi
2.4.1 Business Overview
2.4.1.1 Sanofi Description
2.4.1.2 Sanofi Headquarter, Main Business and Finance Overview
2.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.4.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.4.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.5 ADC Therapeutics
2.5.1 Business Overview
2.5.1.1 ADC Therapeutics Description
2.5.1.2 ADC Therapeutics Headquarter, Main Business and Finance Overview
2.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.5.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.5.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.1 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.2 Global ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.6 Bayer HealthCare
2.6.1 Business Overview
2.6.1.1 Bayer HealthCare Description
2.6.1.2 Bayer HealthCare Headquarter, Main Business and Finance Overview
2.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.6.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.6.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.1 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.2 Global Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.7 Bristol-Myers Squibb
2.7.1 Business Overview
2.7.1.1 Bristol-Myers Squibb Description
2.7.1.2 Bristol-Myers Squibb Headquarter, Main Business and Finance Overview
2.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.7.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.7.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.1 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.2 Global Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.8 Valeant Pharmaceuticals
2.8.1 Business Overview
2.8.1.1 Valeant Pharmaceuticals Description
2.8.1.2 Valeant Pharmaceuticals Headquarter, Main Business and Finance Overview
2.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.8.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.8.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.1 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.2 Global Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.9 Endo Pharmaceuticals
2.9.1 Business Overview
2.9.1.1 Endo Pharmaceuticals Description
2.9.1.2 Endo Pharmaceuticals Headquarter, Main Business and Finance Overview
2.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.9.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.9.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.1 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.2 Global Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
2.10 Foresee Pharmaceuticals
2.10.1 Business Overview
2.10.1.1 Foresee Pharmaceuticals Description
2.10.1.2 Foresee Pharmaceuticals Headquarter, Main Business and Finance Overview
2.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
2.10.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
2.10.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Information
2.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.1 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.2 Global Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share in 2017
3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION, BY MANUFACTURER
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.4.2 Top 5 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET ANALYSIS BY REGIONS
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2013-2018)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2013-2018)
4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2013-2018)
5 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
5.1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.1.4 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.1.5 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
5.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
5.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
5.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
5.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
5.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
6 EUROPE BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
6.1.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.4 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.5 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.6 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.1.7 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
6.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
6.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
7 ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
7.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.5 Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.6 India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
8 SOUTH AMERICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
8.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
8.1.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
8.1.3 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.1.4 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.1.5 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
8.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
8.2.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
8.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
8.3.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
8.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
8.4.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
9 MIDDLE EAST AND AFRICA BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS
9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.4 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.5 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.1.7 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Revenue Share by Application (2013-2018)
10 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SEGMENT BY TYPE
10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2013-2018)
10.2 Alpha-Blocker Sales Growth and Price
10.2.1 Global Alpha-Blocker Sales Growth (2013-2018)
10.2.2 Global Alpha-Blocker Price (2013-2018)
10.3 Phosphodiesterase Type-5 Inhibitors Sales Growth and Price
10.3.1 Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2013-2018)
10.3.2 Global Phosphodiesterase Type-5 Inhibitors Price (2013-2018)
10.4 5-Alpha-Reductase Inhibitors Sales Growth and Price
10.4.1 Global 5-Alpha-Reductase Inhibitors Sales Growth (2013-2018)
10.4.2 Global 5-Alpha-Reductase Inhibitors Price (2013-2018)
11 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SEGMENT BY APPLICATION
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2013-2018)
11.2 Men Sales Growth (2013-2018)
11.3 Women Sales Growth (2013-2018)
12 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET FORECAST (2018-2023)
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2018-2023)
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2018-2023)
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Data Source
LIST OF TABLES AND FIGURES
Figure Benign Prostatic Hyperplasia (BPH) Drugs Picture
Table Product Specifications of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)
Figure Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Types in 2017
Figure Alpha-Blocker Picture
Table Major Manufacturers of Alpha-Blocker
Figure Phosphodiesterase Type-5 Inhibitors Picture
Table Major Manufacturers of Phosphodiesterase Type-5 Inhibitors
Figure 5-Alpha-Reductase Inhibitors Picture
Table Major Manufacturers of 5-Alpha-Reductase Inhibitors
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Applications in 2017
Figure Men Picture
Figure Women Picture
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Table Astellas Pharma Headquarter, Established, Main Business and Finance Overview (2017)
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Eli Lilly Headquarter, Established, Main Business and Finance Overview (2017)
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table GlaxoSmithKline Headquarter, Established, Main Business and Finance Overview (2017)
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Sanofi Headquarter, Established, Main Business and Finance Overview (2017)
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table ADC Therapeutics Headquarter, Established, Main Business and Finance Overview (2017)
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Bayer HealthCare Headquarter, Established, Main Business and Finance Overview (2017)
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Bristol-Myers Squibb Headquarter, Established, Main Business and Finance Overview (2017)
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Valeant Pharmaceuticals Headquarter, Established, Main Business and Finance Overview (2017)
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Endo Pharmaceuticals Headquarter, Established, Main Business and Finance Overview (2017)
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Foresee Pharmaceuticals Headquarter, Established, Main Business and Finance Overview (2017)
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturer (2016-2017)
Figure Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2017
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2013
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2017
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2013
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2013
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries 2017
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries 2017
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2013
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Figure Global Alpha-Blocker Sales Growth (2013-2018)
Figure Global Alpha-Blocker Price (2013-2018)
Figure Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2013-2018)
Figure Global Phosphodiesterase Type-5 Inhibitors Price (2013-2018)
Figure Global 5-Alpha-Reductase Inhibitors Sales Growth (2013-2018)
Figure Global 5-Alpha-Reductase Inhibitors Price (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Figure Global Men Sales Growth (2013-2018)
Figure Global Women Sales Growth (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Regions (2018-2023)
Figure North America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Europe Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Asia-Pacific Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure South America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Middle East and Africa Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List
Figure Benign Prostatic Hyperplasia (BPH) Drugs Picture
Table Product Specifications of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)
Figure Global Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Types in 2017
Figure Alpha-Blocker Picture
Table Major Manufacturers of Alpha-Blocker
Figure Phosphodiesterase Type-5 Inhibitors Picture
Table Major Manufacturers of Phosphodiesterase Type-5 Inhibitors
Figure 5-Alpha-Reductase Inhibitors Picture
Table Major Manufacturers of 5-Alpha-Reductase Inhibitors
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Applications in 2017
Figure Men Picture
Figure Women Picture
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Value) and Growth Rate (2013-2023)
Table Astellas Pharma Headquarter, Established, Main Business and Finance Overview (2017)
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Eli Lilly Headquarter, Established, Main Business and Finance Overview (2017)
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table GlaxoSmithKline Headquarter, Established, Main Business and Finance Overview (2017)
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Sanofi Headquarter, Established, Main Business and Finance Overview (2017)
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table ADC Therapeutics Headquarter, Established, Main Business and Finance Overview (2017)
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Bayer HealthCare Headquarter, Established, Main Business and Finance Overview (2017)
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Bristol-Myers Squibb Headquarter, Established, Main Business and Finance Overview (2017)
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Valeant Pharmaceuticals Headquarter, Established, Main Business and Finance Overview (2017)
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Endo Pharmaceuticals Headquarter, Established, Main Business and Finance Overview (2017)
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Foresee Pharmaceuticals Headquarter, Established, Main Business and Finance Overview (2017)
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Production Bases, Sales Regions and Major Competitors
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2017
Figure Global Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturer (2016-2017)
Figure Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2017
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2013
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2017
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2013
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2013
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries 2017
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries 2017
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2017
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2013
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2017
Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2016-2017)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2016
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2017
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2016-2017)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2016
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2017
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2013-2018)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2013-2018)
Figure Global Alpha-Blocker Sales Growth (2013-2018)
Figure Global Alpha-Blocker Price (2013-2018)
Figure Global Phosphodiesterase Type-5 Inhibitors Sales Growth (2013-2018)
Figure Global Phosphodiesterase Type-5 Inhibitors Price (2013-2018)
Figure Global 5-Alpha-Reductase Inhibitors Sales Growth (2013-2018)
Figure Global 5-Alpha-Reductase Inhibitors Price (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2013-2018)
Figure Global Men Sales Growth (2013-2018)
Figure Global Women Sales Growth (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Regions (2018-2023)
Figure North America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Europe Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Asia-Pacific Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure South America Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Figure Middle East and Africa Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List
